

Correction

Inflammation conditional genome editing mediated by the CRISPR-Cas9 system

Tingting Yuan, Honglin Tang, Xiaojie Xu, Jingjing Shao, Gaojun Wu, Young-Chang Cho,* Yuan Ping,* and Guang Liang*

(iScience 26, 106872, June 16, 2023)

During the preparation of the final versions of the figures, a mislabeling occurred in Figure 5A. Specifically, the promoter of luciferase was labelled as "U6" instead of "NBS." Furthermore, the panel of the confocal fluorescence microscopic images of Hoechst and mCherry in NBS-P65 II-CRISPR group were mistakenly used also for the NBS-P65 I-CRISPR group in Figure 6C. The figures have now been corrected, and the discussion and conclusions of this paper remain unchanged. The authors apologies for any inconvenience caused to the readers.

*Correspondence:
yccho@chonnam.ac.kr (Y.-C.C.),
pingy@zju.edu.cn (Y.P.),
wzmliangguang@163.com (G.L.)
<https://doi.org/10.1016/j.isci.2023.107251>






Figure 5. The AAV9-NBS-CRISPR system could ameliorate liver injury caused by concanavalin A (Con A) (original)




Figure 5. The AAV9-NBS-CRISPR system could ameliorate liver injury caused by concanavalin A (Con A) (corrected)




Figure 6. Optimization of the NBS-CRISPR system (original)




Figure 6. Optimization of the NBS-CRISPR system (corrected)